Important questions for the malignant hematologist to consider when designing or evaluating a study with patient‐reported outcome measures ( <scp>PROMs</scp> )-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Important questions for the malignant hematologist to consider when designing or evaluating a study with patient‐reported outcome measures ( PROMs )

Published:2022-04-29 Issue:1 Volume:109 Page:3-9
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Balitsky Amaris K.¹²^ORCID,D'Souza Anita³⁴,Levine Mark N.¹²

Affiliation:

1. Department of Oncology McMaster University Hamilton Ontario Canada

2. Hamilton Health Sciences ‐ Juravinski Hospital Cancer Centre Hamilton Ontario Canada

3. Center for International Blood and Marrow Transplant Research Milwaukee Wisconsin USA

4. Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13774

Reference48 articles.

1. The Need for a New Medical Model: A Challenge for Biomedicine

2. Evolving Concepts of Patient-Centered Care and the Assessment of Patient Care Experiences: Optimism and Opposition

3. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities

4. New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment

5. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy;BMC Cancer;2024-08-09

2. Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy;2023-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3